Avalon GloboCare Corp. (GENEXOSOME TECHNOLOGIES INC.)
Company Snapshot
Company Overview
GenExosome Technologies Inc., a subsidiary of Avalon GloboCare, is developing exosome-based diagnostics and therapeutic products under the Exosome Isolation System platform.
GenExosome’s pipeline of projects include early detection of oral cancer (saliva), ovarian cancer (plasma) and kidney cancer (urine); skin regeneration and antifibrosis; and treatment of degenerative disorders.
GenExosome markets GET-Exosome Isolation Kits and exosome isolation, sorting and fluorescence labeling services.
In October 2018, GenExosome partnered with Weill Cornell Medicine to standardize processing of cGMP-level exosomes for clinical studies. Weill Cornell will use the GenExosome Exosome Isolation platform. The partners will standardize cGMP-grade exosome isolation from human endothelial cells and identify and isolate tissue-specific exosome for liquid biopsy applications.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
Avalon GloboCare Corp. (GENEXOSOME TECHNOLOGIES INC.) In Reports
Avalon GloboCare Corp. (GENEXOSOME TECHNOLOGIES INC.) In News
Company's Business Segments
- Real Property Operations Expenses : This segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to the company's rental properties.
Applications/End User Industries
- Biotechnology
- Healthcare
- Pharmaceutical
- Life Sciences